LifeVantage Corp.

How big is LifeVantage Corp.?

As of Jun 18, LifeVantage Corp. has a market capitalization of 159.87 million and reported net sales of 222.34 million with a net profit of 9.15 million over the last four quarters. As of Jun 24, the company has shareholder's funds of 25.99 million and total assets of 60.30 million.

As of Jun 18, LifeVantage Corp. has a market capitalization of 159.87 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 222.34 million for the latest four quarters, along with a net profit of 9.15 million during the same period.<BR><BR>As of Jun 24, the latest annual period shows that LifeVantage Corp. has shareholder's funds amounting to 25.99 million and total assets of 60.30 million.

What does LifeVantage Corp. do?

LifeVantage Corporation specializes in bio-hacking aging through nutrigenomics in the Pharmaceuticals & Biotechnology sector, with a market cap of $159.87 million and quarterly net sales of $58 million. Key financial metrics include a P/E ratio of 17.00 and a dividend yield of 1.31%.

Overview:<BR>LifeVantage Corporation is focused on bio-hacking the aging code through nutrigenomics, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Net Sales: 58 Million (Quarterly Results - Mar 2025)<BR>- Net Profit: 3 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 159.87 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 17.00<BR>- Dividend Yield: 1.31%<BR>- Debt Equity: -0.60<BR>- Return on Equity: 26.91%<BR>- Price to Book: 4.70<BR><BR>Contact Details:<BR>- Address: 9785 S Monroe St Ste 300, SANDY UT : 84070-4282<BR>- Tel: 1 801 4329000<BR>- Website: http://www.lifevantage.com/

Should I buy, sell or hold LifeVantage Corp.?

Who are in the management team of LifeVantage Corp.?

As of March 2022, the management team of LifeVantage Corp. includes Independent Chairman Mr. Garry Mauro and Directors Mr. Michael Beindorff, Ms. Erin Brockovich, Mr. Raymond Greer, Mr. Vinayak Hegde, and Mr. Darwin Lewis, who guide the company's strategic direction and governance.

As of March 2022, the management team of LifeVantage Corp. includes the following members of the Board of Directors:<BR><BR>- Mr. Garry Mauro, Independent Chairman of the Board<BR>- Mr. Michael Beindorff, Independent Director<BR>- Ms. Erin Brockovich, Independent Director<BR>- Mr. Raymond Greer, Independent Director<BR>- Mr. Vinayak Hegde, Independent Director<BR>- Mr. Darwin Lewis, Independent Director<BR><BR>These individuals play key roles in guiding the company's strategic direction and governance.

Is LifeVantage Corp. technically bullish or bearish?

As of September 12, 2025, LifeVantage Corp. is in a bearish trend with weak strength indicators, underperforming the S&P 500 with a year-to-date return of -37.82% compared to the S&P's 12.22%.

As of 12 September 2025, the technical trend for LifeVantage Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with a weak strength indicated by the weekly MACD and Bollinger Bands both showing bearish signals. The daily moving averages also confirm a bearish outlook. The KST and Dow Theory present a mildly bullish view on a weekly and monthly basis, but this is overshadowed by the overall bearish indicators. <BR><BR>In terms of performance, LifeVantage has underperformed the S&P 500 across multiple periods, with a significant year-to-date return of -37.82% compared to the S&P's 12.22%.

Is LifeVantage Corp. overvalued or undervalued?

As of October 17, 2025, LifeVantage Corp. is considered very attractive and undervalued, with favorable valuation ratios and strong fundamentals, despite a year-to-date return of -49.74%.

As of 17 October 2025, the valuation grade for LifeVantage Corp. has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company appears undervalued, supported by a P/E ratio of 17, a PEG ratio of 0.11, and an EV to EBITDA ratio of 8.48, which are significantly more favorable compared to its peers. For instance, Chromadex Corp. has a much higher P/E of 39.82, while USANA Health Sciences, Inc. shows an EV to EBITDA of 4.73, highlighting LifeVantage's relative attractiveness in the market.<BR><BR>Despite recent underperformance, with a year-to-date return of -49.74% compared to the S&P 500's 13.30%, LifeVantage's strong fundamentals, including a remarkable ROCE of 96.19% and a solid ROE of 26.91%, suggest that it may be poised for recovery. Overall, the combination of favorable valuation ratios and strong operational metrics supports the conclusion that LifeVantage Corp. is undervalued in the current market landscape.